Skip to main content
Clinical Trials/NCT05881252
NCT05881252
Completed
Not Applicable

An Observational Study of Perinatal Outcomes Following Change in Clinical Criteria in for Treatment of Maternal Hypertension

The University of Texas Health Science Center, Houston1 site in 1 country1,003 target enrollmentMay 11, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Maternal Hypertension
Sponsor
The University of Texas Health Science Center, Houston
Enrollment
1003
Locations
1
Primary Endpoint
Number of patients with Congestive Heart Failure/Pulmonary Edema, hemorrhagic or ischemic Stroke, Acute Kidney Injury (creatinine > 1.5mg/dL), and/or or Myocardial Ischemia.
Status
Completed
Last Updated
9 months ago

Overview

Brief Summary

The purpose of this study is observe outcomes before and after a change in clinical practice in the threshold for management of severe hypertension in pregnancy and the post-partum period. Outcomes will be observed for 10 months under the current (traditional) clinical blood pressure threshold for acute treatment of hypertension, which is >= 160 millimeters of mercury (mmHg) systolic blood pressure (SBP). This will be followed by one month of education about rationale for the new SBP threshold of >= 180 mmHg and change of clinical guidelines. Then, there will be 10 months of observation after adopting the updated clinical threshold for acute antihypertensive treatment (>= 180 SBP).

Registry
clinicaltrials.gov
Start Date
May 11, 2023
End Date
April 4, 2024
Last Updated
9 months ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kristen Cagino

Fellow

The University of Texas Health Science Center, Houston

Eligibility Criteria

Inclusion Criteria

  • any individual \> 20 weeks' gestation in triage or admitted at Children's Memorial Hermann Hospital (CMHH) and with blood pressure with \>= 160/110 mmHg

Exclusion Criteria

  • Active seizure, stroke, Congestive Heart Failure (CHF)/pulmonary edema, acute kidney injury (AKI), or myocardial infarction (MI)
  • A history of stroke, CHF, chronic kidney disease (CKD), MI
  • Have Hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome or thrombocytopenia (platelets \< 100×10\^9/L)
  • Persistent neurologic symptoms including headache \>8/10 one hour after analgesic or blurry vision/loss of vision

Outcomes

Primary Outcomes

Number of patients with Congestive Heart Failure/Pulmonary Edema, hemorrhagic or ischemic Stroke, Acute Kidney Injury (creatinine > 1.5mg/dL), and/or or Myocardial Ischemia.

Time Frame: during the time of delivery hospitalization (about 2 days to 3 months)

The primary outcome is a composite outcome, and will be reported as number of patients who have Congestive Heart Failure/Pulmonary Edema, hemorrhagic or ischemic Stroke, Acute Kidney Injury (creatinine \> 1.5mg/dL), and/or Myocardial Ischemia.

Secondary Outcomes

  • Number of patients with posterior reversible encephalopathy syndrome (PRES)(during the time of delivery hospitalization (about 2 days to 3 months))
  • Number of patients with hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome(during the time of delivery hospitalization (about 2 days to 3 months))
  • Number of patients with non-reassuring fetal heart rate tracing (NR-FHRT) requiring caesarean delivery(at the time of delivery)
  • Number of patients with Apgar score < 7 at 5 min(5 minutes after birth)
  • Number of patients with placental abruption(during the time of delivery hospitalization (about 2 days to 3 months))
  • Number of patients with eclampsia(during the time of delivery hospitalization (about 2 days to 3 months))

Study Sites (1)

Loading locations...

Similar Trials